This is the second paper in our 2-part analysis on managing operating expenses in the new investment environment. In Part 1, our research focused on the traits of successful products launched by emerging biopharma companies (EBP) under the 505(b)(2) regulatory pathway. This analysis focused on financial metrics to measure success, mainly cumulative breakeven, which compared total lifecycle commercial spend against total net revenue.

In Part 2 of our analysis, we shifted our focus to EBP products launched as new chemical entities (NCEs) and Biologics License Applications (BLAs). And, while we have applied the same methodology to measure financial success, we expanded our scope to also incorporate insights into the commercial strategies behind the finances of these products. Download the white paper now to read the full analysis.